Background: Fabry cardiomyopathy (FC) and light-chain amyloid cardiomyopathy (AL) present with concentric left ventricular (LV) hypertrophy/remodeling and diastolic rather than systolic dysfunction. Direct comparisons are difficult due to rarity and confounded by variability of LV thickness.
Aims: To compare LV diastolic and systolic properties between patients with FC and AL in a cohort matched for interventricular septal thickness (IVS).
Methods: A two-center echocardiographic analysis was performed, comprising 118 patients with IVS ≥12 mm (FC and AL 59 patients each) matched by IVS.
Results: Fabry cardiomyopathy patients had larger LV end-diastolic diameter (47.7 [44.0-50.9] vs 45.0 [41.5-49.0] mm, P = 0.002), better LV ejection fraction (EF 68.7 [63.4-74.0] vs 63.0 [54.0-70.0]%, P = 0.001) and midwall fractional shortening (midFS 14.8 [13.0-16.1] vs 12.1 [8.9-15.0]%, P = 0.006). LV EF <40% was rare in both (2% vs 7%, P = 0.17). AL patients expressed higher LV diastolic dysfunction grade (III in 26% vs 4%, II in 21% vs 12% and I in 54% vs 84%, P = 0.004), with higher E/e' ratio (13.6 [10.2-18.8] vs 9.8 [7.5-12.3], P < 0.0001). Average E/e' ratio and midFS were significantly associated with NYHA severity in both groups (P < 0.05 for all).
Conclusions: Matched AL patients had worse LV diastolic function than FC, driven by E/e'. Significant LV systolic dysfunction was rare overall. MidFS and E/e' were associated with heart failure severity in both groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/echo.14144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inferolateral Fibrosis in a Nonhypertrophic Left Ventricle.
JACC Case Rep
November 2024
Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
A 62-year-old recreational cyclist presented with transient loss of consciousness and common electrocardiographic findings. Despite absence of left ventricular hypertrophy, multidisciplinary evaluation and a positive family history led to the diagnosis of non-classical Fabry disease. This case emphasizes the added value of multidisciplinary analysis of nonspecific findings to diagnose a rare disease.
View Article and Find Full Text PDFUnveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies.
Int J Mol Sci
December 2024
Cardiology, Clinical and Molecular Medicine Department, Sapienza University of Rome, 00189 Rome, Italy.
For years, the treatment of many cardiomyopathies has been solely focused on symptom management. However, cardiomyopathies have a genetic substrate, and directing therapy towards the pathophysiology rather than the epiphenomenon of the disease may be a winning strategy. Gene therapy involves the insertion of genes or the modification of existing ones and their regulatory elements through strategies like gene replacement and gene editing.
View Article and Find Full Text PDFCase Report: Diagnostic challenges in Fabry disease: misinterpreted obstructive hypertrophic cardiomyopathy and the role of enzyme replacement therapy.
Front Cardiovasc Med
November 2024
Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder. The abnormal accumulation of metabolic substrates induces inflammation and fibrosis in cells, resulting in organ dysfunction. The clinical manifestations of FD are diverse and non-specific.
View Article and Find Full Text PDFGenotype-Phenotype Spectrum of 52 Mexican Patients With Fabry Disease: A Novel GLA Variant With Atypical Phenotype.
Mol Genet Genomic Med
December 2024
División de Estudios de Posgrado de la Facultad de Medicina, Universidad Nacional Autónoma de, Mexico City, Mexico.
Article Synopsis
- Fabry disease (FD) is a rare genetic disorder caused by mutations in the GLA gene, resulting in various symptoms, and this study analyzed the characteristics of 52 Mexican FD patients.* -
- Common symptoms included acroparesthesias, hypohidrosis, heat intolerance, and proteinuria, with more severe renal and neurological issues observed in males; additional findings included cardiac problems and specific skin manifestations.* -
- The study identified a novel genetic variant associated with an atypical FD phenotype that could resemble Multiple Sclerosis, highlighting the need for renal biopsies for accurate diagnosis when FD is suspected.*
c.640-814T>C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect.
Gene
February 2025
The First Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China; Heart Center, the First Hospital of Lanzhou University, Lanzhou, Gansu, China; Gansu Provincial Clinical Research Center for Cardiovascular Diseases, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. Electronic address:
Article Synopsis
- * Diagnosis was confirmed through endomyocardial biopsy revealing zebra bodies in heart cells, and additional tests showed a specific deep intronic variant affecting the GLA gene and leading to a non-functional truncated protein.
- * The findings suggest that not only is the truncated protein non-functional, but it also inhibits the normal GLA protein's function, emphasizing the need to identify deep intronic mutations for better understanding and treatment of Fabry disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!